Patent · US Active

Organic compositions to treat beta-catenin-related diseases

US10023862B2 · kind B2 · utility

0Cited by

34References

9Claims

0Family size

Assignee

Arrowhead Pharmaceuticals, Inc. · US

Inventors

Brian Bettencourt · Groton, US
David Bumcrot · Belmont, US
Dieter Huesken · Basel, CH
Satyanarayana Kuchimanchi · Cambridge, US
Stuart Milstein · Cambridge, US
Michael R. Schlabach · Cambridge, US
Frank Peter Stegmeier · Acton, US
Markus Warmuth · Natick, US
Jan Weiler · Cambridge, US

Key dates

Filing date	Jan 8, 2013
Grant date	Jul 17, 2018
Priority date	—
Expiry date	Jan 8, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/344
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.